Haleon PLC, a leading player in the bio-tech market viewed favorably for its strong
financial performance, has dominated headlines due to considerable activity in its shares. Major corporations, Pfizer and GSK, have been reducing their stakes in the company, leading to significant changes in shareholder dynamics, echoed vividly with
Pfizer's sell-off of a whopping 700 million shares and GSK ridding itself of a $1.6 billion stake. This has, in turn, caught the attention of
BlackRock, the world's largest asset manager, noticeably increasing its stake in the company. Interestingly, Haleon has been executing a strategic
share buyback program and announced share transactions for key executives, indicating faith in the company. HSBC and Morgan Stanley, however, have revised their ratings and price targets downwards for Haleon, fueling investor speculation. Although Haleon fell slightly short of its Q3 forecasts, citing a stronger pound, it reported strong 2024 financial results, building anticipation for future performance. The firm expects a
profit-skewed H2-2025 and has initiated a shift towards more innovative pursuits, echoing with the $54 million investment in an R&D center in the U.S.
Haleon Stocks News Analytics from Thu, 16 May 2024 07:00:00 GMT to Fri, 14 Mar 2025 13:22:44 GMT -
Rating -1
- Innovation 2
- Information 6
- Rumor -5
